Cumberland Pharmaceuticals (CPIX) risk factors, FY2025 10-K

RISKS RELATED TO OUR BUSINESS

1. 01An adverse development regarding our products could have a material and adverse impact on our future revenues and profitability
2. 02If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues
3. 03Caldolor: We have agreements with multiple manufacturers for the supply of Caldolor. If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Caldolor37% rewritten
4. 04Talicia: The supply of Talicia is complex. The product’s manufacture and supply is overseen by Talicia Holding, Inc., who delivers the product to our warehouse facilitiesNew
5. 05We are dependent on a variety of other third parties. If these third parties fail to perform as we expect, our operations could be disrupted and our financial results could suffer
6. 06Competitive pressures could reduce our revenues and profits
7. 07If generic products that compete with any of our branded pharmaceutical products are approved and sold, sales of our products will be adversely affected
8. 08Any attempt by us to expand the potential market for any of our products is subject to limitations
9. 09Our future growth depends on our ability to identify, acquire rights and successfully integrate new brands into our operations. If we do not successfully identify and acquire rights to products or if we do not successfully integrate acquired product brands into our operations, our growth opportunities may be limited
10. 10Furthermore, other products in development may encounter unforeseen issues during their clinical trials. Any unforeseen issues or lack of FDA approval will negatively affect marketing and development plans for those products
11. 11Our ifetroban product candidates have not been approved for sale and may never be successfully commercialized
12. 12If we are unable to maintain, train and build an effective sales and marketing infrastructure, we will not be able to commercialize and grow our products and product candidates successfully
13. 13If governmental or third-party payors do not provide adequate reimbursement for our products, our revenue and prospects for profitability may be limited
14. 14“Formulary” practices of third-party payors could adversely affect our competitive position
15. 15Continued consolidation of distributor networks in the pharmaceutical industry as well as increases in retailer concentration may limit our ability to profitably sell our products
16. 16Our CET joint initiative may not result in our gaining access to commercially viable products
17. 17We depend on our key personnel, the loss of whom would adversely affect our operations. If we fail to attract and retain the talent required for our business, our business will be materially harmed
18. 18The size of our organization and our potential growth may lead to difficulties in managing operations
19. 19We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product or product candidate and may have to limit its commercialization
20. 20We have product liability insurance that covers our clinical trials, the marketing and sale of our products up to a $10 million annual aggregate limit, subject to specified deductibles. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us
21. 21Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated
22. 22Our business and operations would suffer in the event of system failures, security breaches, including any cybersecurity incidents, adverse events or other disruptions within our information technology infrastructure at our corporate headquarters; or in the event of intellectual property infringement
23. 23We license our products globally; therefore, we may have exposure to foreign regulatory requirements and fluctuations in foreign currency exchange rates
24. 24We may decide not to commercialize one of our drug candidates once it obtains regulatory approval if we determine that commercialization of that product would require more capital and time than we are willing to invest
25. 25Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community
26. 26We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and prospects
27. 27We may become subject to litigation or governmental investigations in the United States and foreign jurisdictions that may arise from the conduct of our business. Like many companies in our industry, we have from time to time received inquiries and other types of information requests from government authorities

RISKS RELATING TO GOVERNMENT REGULATION

1. 28Proposed legislation may permit re-importation of drugs from other countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could materially and adversely affect our operating results and our overall financial condition50% rewritten
2. 29Legislative and regulatory changes affecting pricing of pharmaceutical products could materially and adversely affect our operating results and our overall financial conditionNew
3. 30We must comply with the CREATES Act
4. 31We must comply with the Foreign Corrupt Practices Act
5. 32We must comply with the Physician Payment Sunshine Act76% rewritten
6. 33We must comply with healthcare fraud and abuse laws and regulationsNew
7. 34We may be subject to laws and regulations governing our use of Artificial IntelligenceNew

RISKS RELATING TO INTELLECTUAL PROPERTY

1. 35Our strategy to secure and extend marketing exclusivity or patent rights may provide only limited or no protection from competition
2. 36As discussed in Part I, Item 1, Business - Patents, Trademarks, and Other Intellectual Proprietary Rights, of this report on Form 10-K, we have several patents for formulations of Acetadote, and have previously engaged in litigation to enforce our patent rights
3. 37If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
4. 38We may depend on certain licensors for the maintenance and enforcement of intellectual property rights and have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf
5. 39If the use of our technology conflicts with the intellectual property rights of third parties, we may incur substantial liabilities, and we may be unable to commercialize products based on this technology in a profitable manner or at all
6. 40We may be involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be costly and time consuming
7. 41We may be involved in lawsuits to protect or enforce our trademarks or for allegedly infringing the trademark rights of others, which could be costly and time consuming
8. 42If we breach any of the agreements under which we license rights to our products and product candidates from others, we could lose the ability to continue commercialization of our products and development and commercialization of our product candidates
9. 43We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers

RISKS RELATED TO OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS

1. 44Our operating results are likely to fluctuate from period to period
2. 45Our focus on acquisitions as a growth strategy has created intangible assets whose amortization could negatively affect our results of operations
3. 46We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce or eliminate our product development or commercialization and marketing efforts
4. 47We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including clinical trials prior to seeking regulatory approval, that are required before we can sell a drug productNew
5. 48Our officers, directors, and principal shareholders, acting as a group, could significantly influence corporate actions21% rewritten
6. 49Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports

RISKS RELATED TO OWNING OUR STOCK

1. 50The market price of our common stock may fluctuate substantially29% rewritten
2. 51Unstable market conditions may have serious adverse consequences on our business
3. 52We may not be able to maintain our listing on the NASDAQ Global Select Market (“NASDAQ”), which could have a material adverse effect on us and our stockholders
4. 53Some provisions of our fourth amended and restated charter, bylaws and Tennessee law may inhibit potential acquisition bids that you may consider favorable
5. 54We have never paid cash dividends on our capital stock
6. 55Our Revolving Credit Agreement imposes restrictive and financial covenants on us. Our failure to comply with these covenants could trigger events that would have a material adverse effect on our business
7. 56We have risks related to interest rates